Investor Relations

We Are a Biotech Royalty Aggregator With 120-Plus Assets and Growing

XOMA Royalty plays a unique role in helping biotech companies achieve their goal of improving human health. We do this by acquiring the economic rights to future milestone and royalty payments associated with partnered pre-commercial clinical candidates. In return the seller receives non-dilutive, non-recourse funding to advance their internal drug candidate(s).

Download Presentation

Company & Portfolio News

Apr 23, 2025

2025 Letter to Stockholders

View Press Release View All News

May 09, 2024

2024 Letter to Shareholders

Dec 19, 2023

XOMA raises up to $140M with Blue Owl Capital

Apr 30, 2023

2023 Letter to Shareholders

Latest Press Releases

Jan 12, 2026 • 7:30 AM EST

XOMA Royalty Announces CFO Transition

Dec 30, 2025 • 7:30 AM EST

XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab

Dec 22, 2025 • 7:30 AM EST

XOMA Royalty Declares Quarterly Preferred Stock Dividends

View All Press Releases

Corporate Presentation

View Presentation

Q3 2025

Quarter Ended Sep 30, 2025

Earnings Release

PDF HTML

10-Q

PDF HTML

XBRL

ZIP HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2024

For complete information regarding our financials, see our periodic filings

For Holders of XOMA Royalty Preferred Stock

IRS Form 8937

Stock Snapshot

View Detailed Stock Information

Company Overview

XOMA Royalty has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies. The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. Many of these licenses are the result of XOMA Royalty's pioneering efforts in the discovery and development of antibody therapeutics. The Company’s royalty-aggregator business model includes acquiring additional licenses to programs with third-party funding.

View Board of Directors

XOMA Royalty Corporation at a Glance

120+

Total assets

Assets with large-cap partners

11+

Therapeutic categories

Investor Contact Information

Company

XOMA Royalty Corporation
2200 Powell Street
Suite 310
Emeryville, CA 94608